Sharda Cropchem Ltd
Sharda Cropchem is principally engaged in export of agrochemicals (technical grade and formulations) and non-agro products such as conveyor belts, rubber belts/sheets, dyes and dye intermediates to various countries across the world.
- Market Cap ₹ 4,303 Cr.
- Current Price ₹ 476
- High / Low ₹ 769 / 369
- Stock P/E 13.4
- Book Value ₹ 214
- Dividend Yield 1.26 %
- ROCE 26.2 %
- ROE 19.7 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 19.0%
- Company's median sales growth is 17.0% of last 10 years
Cons
- Company has high debtors of 157 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Agro Chemicals Industry: Pesticides / Agrochemicals - Indian
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
442 | 614 | 778 | 790 | 1,061 | 1,222 | 1,399 | 1,707 | 1,998 | 2,003 | 2,396 | 3,580 | 3,998 | |
362 | 492 | 639 | 630 | 878 | 941 | 1,075 | 1,343 | 1,621 | 1,653 | 1,945 | 2,884 | 3,383 | |
Operating Profit | 80 | 121 | 138 | 160 | 183 | 281 | 324 | 364 | 376 | 350 | 450 | 696 | 615 |
OPM % | 18% | 20% | 18% | 20% | 17% | 23% | 23% | 21% | 19% | 17% | 19% | 19% | 15% |
8 | 8 | 16 | 32 | 25 | 23 | 14 | 9 | -22 | -12 | 46 | 29 | 36 | |
Interest | 0 | 0 | 0 | 8 | 9 | 8 | 9 | 15 | 20 | 16 | 16 | 15 | 3 |
Depreciation | 37 | 43 | 37 | 29 | 23 | 35 | 56 | 70 | 99 | 137 | 170 | 245 | 252 |
Profit before tax | 51 | 86 | 118 | 155 | 175 | 261 | 272 | 287 | 235 | 185 | 309 | 464 | 396 |
Tax % | 19% | 21% | 28% | 29% | 30% | 33% | 30% | 34% | 25% | 11% | 26% | 25% | |
Net Profit | 41 | 68 | 84 | 111 | 123 | 175 | 190 | 191 | 176 | 165 | 229 | 349 | 320 |
EPS in Rs | 22.96 | 7.62 | 9.35 | 12.31 | 13.63 | 19.41 | 21.11 | 21.14 | 19.55 | 18.25 | 25.40 | 38.71 | 35.48 |
Dividend Payout % | 0% | 0% | 0% | 16% | 18% | 21% | 19% | 19% | 20% | 22% | 20% | 16% |
Compounded Sales Growth | |
---|---|
10 Years: | 19% |
5 Years: | 21% |
3 Years: | 21% |
TTM: | 24% |
Compounded Profit Growth | |
---|---|
10 Years: | 18% |
5 Years: | 13% |
3 Years: | 19% |
TTM: | 5% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 5% |
3 Years: | 64% |
1 Year: | -10% |
Return on Equity | |
---|---|
10 Years: | 18% |
5 Years: | 17% |
3 Years: | 17% |
Last Year: | 20% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Sep 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
18 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | |
Reserves | 302 | 303 | 377 | 466 | 564 | 715 | 870 | 1,045 | 1,194 | 1,313 | 1,524 | 1,822 | 1,840 |
2 | 3 | 46 | 40 | 38 | 2 | 0 | 170 | 0 | 0 | 81 | 47 | 23 | |
168 | 237 | 284 | 319 | 354 | 522 | 686 | 914 | 914 | 940 | 1,163 | 1,779 | 1,399 | |
Total Liabilities | 489 | 634 | 796 | 914 | 1,047 | 1,329 | 1,646 | 2,219 | 2,198 | 2,343 | 2,858 | 3,738 | 3,353 |
88 | 58 | 64 | 64 | 88 | 130 | 210 | 226 | 372 | 416 | 544 | 592 | 910 | |
CWIP | 34 | 63 | 88 | 133 | 149 | 210 | 232 | 360 | 220 | 161 | 131 | 212 | 0 |
Investments | 30 | 36 | 97 | 174 | 95 | 90 | 61 | 22 | 212 | 116 | 83 | 134 | 75 |
339 | 476 | 547 | 542 | 715 | 899 | 1,143 | 1,611 | 1,394 | 1,650 | 2,099 | 2,800 | 2,368 | |
Total Assets | 489 | 634 | 796 | 914 | 1,047 | 1,329 | 1,646 | 2,219 | 2,198 | 2,343 | 2,858 | 3,738 | 3,353 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
156 | 46 | 197 | 181 | 17 | 556 | 146 | 246 | 267 | ||||
-145 | -19 | -113 | -104 | -160 | -351 | -59 | -282 | -205 | ||||
-22 | -24 | -89 | -38 | 132 | -215 | -60 | 43 | -91 | ||||
Net Cash Flow | -11 | 3 | -6 | 40 | -11 | -11 | 27 | 8 | -29 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 205 | 194 | 178 | 185 | 156 | 185 | 175 | 191 | 148 | 180 | 177 | 157 |
Inventory Days | 68 | 89 | 62 | 57 | 72 | 74 | 117 | 169 | 96 | 100 | 117 | 130 |
Days Payable | 138 | 152 | 130 | 146 | 117 | 179 | 186 | 202 | 167 | 180 | 180 | 172 |
Cash Conversion Cycle | 135 | 131 | 111 | 97 | 111 | 81 | 106 | 158 | 77 | 100 | 114 | 115 |
Working Capital Days | 121 | 121 | 101 | 85 | 95 | 96 | 99 | 130 | 71 | 101 | 105 | 92 |
ROCE % | 17% | 24% | 26% | 28% | 27% | 36% | 32% | 27% | 23% | 18% | 21% | 26% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
8 Feb - The officials of the Company will be meeting Investors/Analysts (Participants) as per the details below. Date - 8th February 2023 Type of Interaction - In-person …
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
25 Jan - Dear Sir/Madam, The Un-audited Financial Results (Standalone & Consolidated) for the quarter and nine months ended 31st December, 2022 have been approved and taken on …
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
25 Jan - The Audio Link for the conference call with the Analysts/ Investors for the Q3 & FY 2022-23 Financial Results of the Company conducted through digital …
- The Declaration Of Interim Dividend For The Financial Year 2022-23. 24 Jan
-
Announcement under Regulation 30 (LODR)-Investor Presentation
24 Jan - Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015 (Listing Regulations), we are enclosing herewith the presentation to be made to the …
Annual reports
Concalls
-
Jan 2023TranscriptNotesPPT
-
Oct 2022TranscriptNotesPPT
-
Jul 2022TranscriptNotesPPT
-
May 2022TranscriptNotesPPT
-
Jan 2022Transcript PPT
-
Oct 2021Transcript PPT
-
Jul 2021Transcript PPT
-
May 2021Transcript PPT
-
Jan 2021Transcript PPT
-
Oct 2020Transcript PPT
-
Aug 2020Transcript PPT
-
Jun 2020Transcript PPT
-
Jan 2020Transcript PPT
-
Oct 2019Transcript PPT
-
Jul 2019Transcript PPT
-
May 2019Transcript PPT
-
Jan 2019Transcript PPT
-
Oct 2018Transcript PPT
-
Jul 2018Transcript PPT
-
May 2018Transcript PPT
-
Jan 2018Transcript PPT
-
Oct 2017Transcript PPT
-
Jul 2017TranscriptPPT
-
May 2017Transcript PPT
-
Jan 2017Transcript PPT
-
Nov 2016Transcript PPT
-
Aug 2016TranscriptPPT
-
May 2016TranscriptNotesPPT
-
Jan 2016Transcript PPT
Asset Light Business Model [1]
The company follows an asset light business model as they focus on Identification of generic molecules, preparing dossiers, seeking registrations, marketing & distributing formulation. The company outsources the manufacturing of AI's and other formulations and this has resulted in cost competitiveness across various geographies.